Management team

James Culverwell

James Culverwell

Chairman

James Culverwell has over 30 years’ experience in the pharmaceutical industry in pharmaceutical company analysis, investment banking and healthcare private equity. Mr. Culverwell established leading global healthcare research franchises at Hoare Govett and Merrill Lynch & Co. In 2004, Mr. Culverwell set up Sudbrook Associates, a healthcare corporate advisor specialising in fund raising, corporate advice and due diligence in the private healthcare sector. Mr. Culverwell was a Non Executive Director and Chairman of the Audit Committee of Innocoll Holdings quoted on Nasdaq until its sale in 2016 and is currently a Non Executrive Director of Amryt Pharma, a rare disease company listed on AIM, and where he also chairs the audit committees. Mr. Culverwell received a MSc from the University of Aberdeen.

Karl Keegan

Karl Keegan

Chief Executive Officer

Karl Keegan has over 20 years’ experience in the pharmaceutical industry including working in R&D and strategic product development at SmithKline Beecham. He has worked for a number of major investment banks as a biotechnology analyst including Dresdner Kleinwort Benson, UBS and Bank of America and was on the global executive team and Board Director of Canaccord. Subsequently he has held a number of CFO and corporate development roles at biotechnology and specialty pharma companies including Minster Pharmaceuticals plc, Pharming Group NV, Vectura Group plc and Shield Therapeutics plc. Karl has a BSc degree in pharmacology from University College, Dublin, Ireland, MPhil and PhD degrees from the University of Cambridge, UK and a MSc in finance from London Business School, UK.

Professor Hardev Pandha

Professor Hardev Pandha

Founder

Professor Pandha qualified as a doctor at the University of Birmingham and has trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School, Hammersmith Hospital. He spent four years in research at the CRUK labs at the Hammersmith to gain his PhD in gene therapy, for which he was awarded the McElwain prize. He completed his training at Stanford University in the USA and the Royal Marsden Hospital in London. He was a consultant medical oncologist at St Georges University of London in 2000 before his appointment as Professor of Medical Oncology at Surrey University in 2006. He has been director of the Surrey Cancer Research Institute (SCRI) since 2014.

Professor Pandha specialises in the treatment of prostate, kidney and bladder cancer, and advises a number of companies in early phase clinical trials of experimental cancer treatments in these fields. As a full professor at the University of Surrey, he leads a group of 22 scientists, doctors, nurses, technicians and research students. His research focuses on the development of new cancer biomarkers, new cancer therapies using the immune system (immunotherapy, cancer vaccines), live viruses (viral therapy) and small molecules. His group is particularly interested in the family of HOX genes, which normally control limb and organ growth in the embryo, but which drive cancer cell growth in adults. His team discovered the new test for prostate and bladder cancers, called EN2, a member of this HOX gene family, which is now undergoing final evaluation.

Professor Pandha has published over 200 scientific papers and contributed to 14 medical textbooks. He has been a member of advisory boards in the management of urological cancers and on the editorial board of several medical journals.

Professor Richard Morgan

Professor Richard Morgan

Founder

Professor Morgan graduated in natural sciences from the University of Cambridge in 1990 and gained his doctorate in biochemistry from the University of Birmingham in 1993. In the following years he was postdoctoral scientist at the MRC National Institute for Medical Research, London (1993-1997) and at the Hubrecht Laboratory for Developmental Biology, Utrecht, The Netherlands (1997-2000). Subsequently he held the posts of lecturer in cell and developmental biology, St. George's, University of London (2000-2006) and senior lecturer in Molecular Oncology, University of Surrey (2006-2014), and then in 2014 he became Professor of Molecular Oncology at Bradford University and in February 2016 he accepted the Directorship of the prestigious Institute of Cancer Therapeutics. Professor Morgan’s group is working on the HOX and TMEM92 projects described above along with a number of other studies of new molecular targets in cancer.

Dr. Stephen Shuttleworth

Dr. Stephen Shuttleworth

Independent Non-Executive Director

Stephen was appointed as a Non-Executive Director at Hox Therapeutics in January 2019. He is joint CSO/COO of Karus Therapeutics, Oxfordshire, whom he joined in 2008 as the founding scientist of the company’s PI3K-p110β/δ and HDAC6 inhibitor programs, and where he designed and directed the development of the oral small molecule anti-tumour agents KA2237 and KA2507 from concept to Phase I clinical trials. In January 2019, Stephen was also appointed Entrepreneur-in-Residence at Samsara BioCapital, California.

Previously, Stephen held R&D leadership positions in UK and North American biotech, working in several disease areas across multiple therapeutic targets, notably at Chiroscience, BiochemPharma, Tularik, CRUK and Piramed. At Piramed, he directed the PI3K programs, designing and leading the preclinical development of Pictilisib, partnered with Genentech and subsequently taken into Phase II by Roche, who acquired Piramed for $160M in 2008. He obtained his BSc and PhD in Chemistry from the University of Liverpool, has published extensively, and has been an invited speaker at multiple international conferences. In 2007 he was appointed a Fellow of the Royal Society of Chemistry, and in 2014 an Honorary Professor (Molecular & Clinical Cancer Sciences, School of Medical Science) at the University of Manchester.